Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Current advances in cancer vaccines targeting NY-ESO-1 for solid cancer treatment

5 Sept 2023

Abstract excerpt

New York-esophageal cancer 1 (NY-ESO-1) belongs to the cancer testis antigen (CTA) family, and has been identified as one of the most immunogenic tumor-associated antigens (TAAs) among the family members. Given its ability to trigger spontaneous humoral and cellular immune response and restricted expression, NY-ESO-1 has emerged as one of the most promising targets for cancer immunotherapy. Cancer vaccines, an...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer Immunotherapy and Biomarkers
Share to Immune Cell Function and Interaction
Share to Immunotherapy and Immune Responses

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 37731507
DOI: 10.3389/fimmu.2023.1255799

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Current advances in cancer vaccines targeting NY-ESO-1 for solid cancer treatmentPMID 37731507Read ↗

NY-ESO-1 protein formulated in ISCOMATRIX adjuvant is a potent anticancer vaccine inducing both humoral and CD8+ t-cell-mediated immunity and protection against NY-ESO-1+ tumors.Semantic proximity Read ↗

Identification of NY-ESO-1 epitopes presented by human histocompatibility antigen (HLA)-DRB4*0101-0103 and recognized by CD4(+) T lymphocytes of patients with NY-ESO-1-expressing melanoma.Semantic proximity Read ↗

Multiepitope CD8+ T cell response to a NY-ESO-1 peptide vaccine results in imprecise tumor targetingSemantic proximity Read ↗

One NY-ESO-1-derived epitope that promiscuously binds to multiple HLA-DR and HLA-DP4 molecules and stimulates autologous CD4+ T cells from patients with NY-ESO-1-expressing melanoma.Semantic proximity Read ↗

Cancer Vaccines: Recent Insights and Future DirectionsSemantic proximity Read ↗

Effective NY-ESO-1–specific MHC II–restricted T cell receptors from antigen-negative hosts enhance tumor regressionSemantic proximity Read ↗

Strategy for monitoring T cell responses to NY-ESO-1 in patients with any HLA class I allele.Semantic proximity Read ↗

Cancer Vaccines: Antigen Selection StrategySemantic proximity Read ↗

Engineered CD4 TCR T cells with conserved high-affinity TCRs targeting NY-ESO-1 for advanced cellular therapies in cancerSemantic proximity Read ↗

Efficient targeting of NY-ESO-1 tumor antigen to human cDC1s by lymphotactin results in cross-presentation and antigen-specific T cell expansionSemantic proximity Read ↗

NY-ESO-1 expression predicts an aggressive phenotype of ovarian cancer.Semantic proximity Read ↗

Quantitative and qualitative assessment of circulating NY-ESO-1 specific CD4+ T cells in cancer-free individuals.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.